We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+11.52%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.05B
AUM Growth
+$69.9M
Cap. Flow
+$13.5M
Cap. Flow %
1.29%
Top 10 Hldgs %
49.49%
Holding
62
New
15
Increased
22
Reduced
15
Closed
8

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$28.7M
2
MOH icon
Molina Healthcare
MOH
+$27.6M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$26.9M
4
PRTA icon
Prothena Corp
PRTA
+$21.2M
5
NVRO
NEVRO CORP.
NVRO
+$18.2M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$48.6M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$45.2M
3
SAGE
Sage Therapeutics
SAGE
+$33.8M
4
AGN
Allergan plc
AGN
+$30.7M
5
PEN icon
Penumbra
PEN
+$21.8M

Sector Composition

Rank Sector Weight
1 Healthcare 73.5%
2 Financials 2.71%
3 Communication Services 2.42%
4 Industrials 0.75%
5 Consumer Staples 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$68.2M 6.51%
19,150,650
– –
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$60.6M 5.79%
11,106,446
+388,026
+4% +$2.71M
MDVN
3
DELISTED
MEDIVATION, INC.
MDVN
$56.1M 5.35%
929,529
-857,070
-48% -$48.6M
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$55.8M 5.33%
1,381,477
+411,356
+42% +$15.6M
ATRA icon
5
Atara Biotherapeutics
ATRA
$74.7M
$54.2M 5.18%
96,359
+5,328
+6% +$2.56M
PEN icon
6
Penumbra
PEN
$12.5B
$51.4M 4.91%
863,581
-404,386
-32% -$21.8M
ELGX
7
DELISTED
Endologix Inc
ELGX
$49.4M 4.72%
396,275
+149,390
+61% +$17.2M
CLVS
8
DELISTED
Clovis Oncology, Inc.
CLVS
$42.5M 4.06%
3,097,850
-1,486
-0% -$21.7K
MOH icon
9
Molina Healthcare
MOH
$12B
$42.2M 4.03%
845,360
+516,347
+157% +$27.6M
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$37.7M 3.6%
971,565
-84,494
-8% -$3.04M
PTLA
11
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$34.6M 3.31%
1,466,537
+576,930
+65% +$14.2M
NVRO
12
DELISTED
NEVRO CORP.
NVRO
$29.4M 2.81%
398,371
+267,800
+205% +$18.2M
BSX icon
13
Boston Scientific
BSX
$65.1B
$28.8M 2.75%
1,230,320
-102,200
-8% -$2.21M
XBI icon
14
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$26.6M 2.54%
+490,900
New +$26.9M
MODN
15
DELISTED
MODEL N, INC.
MODN
$25.4M 2.42%
1,900,659
+15,300
+0.8% +$180K
BMRN icon
16
BioMarin Pharmaceuticals
BMRN
$11.4B
$25.1M 2.4%
322,394
-155,893
-33% -$13.3M
NSTG
17
DELISTED
NanoString Technologies, Inc.
NSTG
$24.6M 2.35%
1,949,185
+86,150
+5% +$1.25M
INCY icon
18
Incyte
INCY
$23.1B
$24.2M 2.31%
302,307
+85,713
+40% +$6.65M
BKD icon
19
Brookdale Senior Living
BKD
$3.57B
$23.9M 2.28%
1,545,331
+116,400
+8% +$2.03M
ALXN
20
DELISTED
Alexion Pharmaceuticals
ALXN
$23.6M 2.26%
+202,400
New +$28.7M
HTWR
21
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$23.4M 2.24%
405,497
+190,726
+89% +$6.24M
WVE icon
22
Wave Life Sciences
WVE
$1.1B
$22.7M 2.16%
1,095,473
-142,800
-12% -$2.22M
AET
23
DELISTED
Aetna Inc
AET
$22.4M 2.14%
183,225
-8,400
-4% -$965K
CNC icon
24
Centene
CNC
$32.5B
$20.4M 1.94%
570,286
-370,812
-39% -$11.6M
PRTA icon
25
Prothena Corp
PRTA
$454M
$17M 1.63%
+487,406
New +$21.2M
1
2 3

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q2 2016 Portfolio in Review

As of Q2 2016, Redmile Group held 62 positions worth $1.05B, up 7.1% from $977M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group's Q2 2016 filing shows 15 new, 22 increased, 15 reduced and 8 closed positions. Its largest new stake was Alexion Pharmaceuticals: 202,400 shares worth $23.6M. The largest sale was MEDIVATION, INC., an estimated $48.6M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 77% a quarter earlier, followed by Financials and Communication Services.

  • Redmile Group's largest Q2 2016 buy was Alexion Pharmaceuticals: 202,400 shares worth $23.6M.
  • Redmile Group added most to Molina Healthcare in Q2 2016, an estimated $27.6M increase.
  • Redmile Group's biggest Q2 2016 reduction was MEDIVATION, INC., cutting an estimated $48.6M.
  • Redmile Group fully exited Sage Therapeutics in Q2 2016, selling an estimated $33.8M.
  • Redmile Group's ten largest holdings make up 49% of its $1.05B portfolio in Q2 2016.
  • Redmile Group opened 15 new positions and closed 8 in Q2 2016.
  • Redmile Group's portfolio value rose 7.1% quarter-over-quarter to $1.05B.

Based on Redmile Group's 13F filing for Q2 2016, filed 16 Aug 2016.